Abstract 244: Anticoagulant Options and Inpatient Costs for Patients with Non-Valvular Atrial Fibrillation [Session Title: Poster Session II]

Conclusion: In propensity-matched cohorts of NVAF patients treated with warfarin or rivaroxaban, a TSOAC, our data demonstrated significant index and overall hospital cost reductions associated with the TSOAC strategy.

Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Laliberte, F., Pilon, D., Raut, M. K., Nelson, W. W., Olson, W. H., Germain, G., Schein, J. R., Lefebvre, P. Tags: Session Title: Poster Session II Source Type: research